Your shopping cart is currently empty

DS-003 is a small molecule Gp120 inhibitor. As an analog of BMS-378806, DS003 demonstrates enhanced inhibitory activity during prolonged exposure and when used in combination with fusion inhibitors. However, prior exposure to soluble CD4+ hinders DS003's binding to the viral envelope. Studies indicate that due to its targeting of the CD4+ binding site on Gp120, DS003 is a promising candidate for pre-exposure prophylactic therapy.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | DS-003 is a small molecule Gp120 inhibitor. As an analog of BMS-378806, DS003 demonstrates enhanced inhibitory activity during prolonged exposure and when used in combination with fusion inhibitors. However, prior exposure to soluble CD4+ hinders DS003's binding to the viral envelope. Studies indicate that due to its targeting of the CD4+ binding site on Gp120, DS003 is a promising candidate for pre-exposure prophylactic therapy. |
| Synonyms | DS003, DS 003, BMS-599793, BMS599793, BMS 599793 |
| Molecular Weight | 478.5 |
| Formula | C27H22N6O3 |
| Cas No. | 676489-50-2 |
| Smiles | N#CC(C=1C=CC=CC1)=C2CCN(C(=O)C(=O)C3=CNC=4C(=NC=C(OC)C34)C=5N=CC=NC5)CC2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.